Moreover, it has been shown that TAK1 inhibition, mediated by RNAi-silencing or a TAK1 inhibitor, significantly reduced NF-κB expression, sensitizing pancreatic cancer cells to gemcitabine-induced cell-death [28]. This evidence concerns the gene MAP3K7 and pancreatic neoplasm.